Immunovant, Inc. IMVT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s total liabilities & equity?
- Immunovant, Inc. (IMVT) reported total liabilities & equity of $957.01M in Q1 2026.
- How has Immunovant, Inc.'s total liabilities & equity changed year-over-year?
- Immunovant, Inc.'s total liabilities & equity increased by 23.3% year-over-year, from $776.22M to $957.01M.
- What is the long-term trend for Immunovant, Inc.'s total liabilities & equity?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s total liabilities & equity has grown at a 18.3% compound annual growth rate (CAGR), from $412.49M to $957.01M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.